Photo Credit: GCShutter / Getty Images
Ashley Ringstaff, Leander, TX.
Brian Phillips, St. Louis.
Cleveland Clinic: “Ocrelizumab.”
Cleveland Clinic Mellen Center for Multiple Sclerosis: “Mellen Center Approach to Ocrelizumab (Ocrevus).”
Human Vaccines and Immunotherapeutics: “Anti-CD20 monoclonal antibodies: reviewing a revolution.”
Immunological Medicine: “B-cell depletion therapy for multiple sclerosis.“
Mayo Clinic: “Multiple sclerosis: Diagnosis & treatment,” “Ofatumumab (Intravenous Route, Subcutaneous Route),” and “Ocrelizumab (Intravenous Route).”
Multiple Sclerosis Society of America: “Long-Term Treatments for Multiple Sclerosis.”
Multiple Sclerosis Trust (UK): “How do I take Ocrevus?”
National Cancer Institute: “B cell.”
National Human Genome Research Institute: “Antibody.”
NeurologyAdvisor: “MS Drug Developments: Utility of CD20-Targeted B-Cell Therapy for Relapsing Multiple Sclerosis.”
Novartis Pharmaceuticals Corp.: “Kesimpta (ofatumumab): Understanding Side Effects.”